SCHEMBL6468352

SCHEMBL6468352

CON(C)C(=O)C(CCNC(=O)OCc1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SLC1A3 P43003 1/20 0.49
SLC1A1 P43005 1/20 0.49
L3MBTL1 Q9Y468 3/20 0.48
HTT P42858 1/20 0.48
FOLH1 Q04609 2/20 0.47
MAPT P10636 1/20 0.45
OPRK1 P41145 1/20 0.44
CTSL P07711 3/20 0.44
CTSS P25774 3/20 0.44
CTSB P07858 2/20 0.44
CTSK P43235 2/20 0.44
TGM2 P21980 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA4 P43681 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7799710 0.91 SLC1A3 (0.42) LMNASMN1; SMN2SLC1A3SLC1A1L3MBTL1
SCHEMBL22982284 0.88 MEN1 (0.47) LMNASMN1; SMN2HTTOPRK1CTSL
SCHEMBL5172763 0.88 MEN1 (0.47) LMNASMN1; SMN2HTTOPRK1CTSL
SCHEMBL6466556 0.84 MTNR1A (0.44) MEN1KMT2A
SCHEMBL28088132 0.82 SLC1A3 (0.61) LMNASMN1; SMN2SLC1A3SLC1A1L3MBTL1
SCHEMBL7047961 0.82 JAK3 (0.51) MAPTCTSSCTSKMEN1KMT2A
SCHEMBL3720455 0.82 JAK3 (0.51) MAPTCTSSCTSKMEN1KMT2A
SCHEMBL15745834 0.81 FOLH1 (0.57) LMNASMN1; SMN2HTTFOLH1TGM2
SCHEMBL30340611 0.80 DPP8 (0.60) SLC1A3SLC1A1HTTFOLH1TGM2
SCHEMBL3255270 0.78 ATM (0.60) LMNASMN1; SMN2OPRK1CTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1516877-A1 Amine derivatives as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-03-23 EP disclosed
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-12-18 US disclosed
US-6576630-B1 Alkanoyl substituted benzooxazoles or naphthooxazoles AXYS PHARMACEUTICALS, INC. 2003-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors SERPINB1, CTRL, CTSZ LMNA 1755/4885SMN1; SMN2 4034/4885SLC1A3 4389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.